Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacotherapy 1 > Exam 1 > Flashcards

Exam 1 Flashcards

1
Q

Use the 7-steps to systemically answer a drug information question.

A
  1. Secure demographics of requestor
  2. Obtain background information
  3. Determine and categorize the ultimate question
  4. Develop strategy and conduct search
  5. Perform evaluation, analysis, and synthesis
  6. Formulate and provide response
  7. Conduct follow-up and documentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

7 steps to answer DI question: Secure demographics of requestor

A

Know your audience and how to effectively communicate

Medical jargon with pt vs physician

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

7 steps to answer DI question: Obtain background information

A

Use gathered info form pt to determine effects of any other health problems etc that would need to be accommodated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

7 steps to answer DI question: Determine and categorize the ultimate question

A

Determine correct pt population affected and use appropriate resources
Pregnancy and lactation resources etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

7 steps to answer DI question: Develop strategy and conduct search

A

Start with tertiary and follow lit hierarchy

EFFICIENCY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

7 steps to answer DI question: Perform evaluation, analysis, and synthesis

A

Use background info & consult other professionals to gain an objective view

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

7 steps to answer DI question: Formulate and provide response

A

Determine best option, be aware of other options & present them with citations to the requestor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

7 steps to answer DI question: Conduct follow-up and documentation

A

Make sure correct person recieved info and keep as reference for later

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

State and incorporate the 4-D’s of problem-solving into answering a question.

A

(define, design, do, debrief)

Define problem that needs solving
Design a plan to solve the problem
Do to plan
Debrief with an evidence-based recommendation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define and describe “evidence-based medicine (EBM)”.

A

Integration of best research with clinical expertise & patient values

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe a disease state practice guideline

A

“Directions” to diagnose and treat pts with a specific disease
&
Prepared by an expert panel coordinated by an organization or governing body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

“Directions” to diagnose and treat pts with a specific disease

A

Based upon the best evidence at a given time → guidelines do change over time due to new findings (results of primary lit)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

who is a part of the panel developing practice guidelines?

A

Panel with practitioners specialized in area of disease → usually involved with research for better understanding of disease and therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how does the P/G panel rank evidence?

A

Panel searches lit for research evaluating new diagnostic techniques and/or therapies

Research evaluated to determine primary lit strengths and limitations

Research is graded (excellent to poor) by panel

P/G include recommendations with a grade of evidence level ( strong vs weak)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

study designs with one vs few vs many subjects

A

One: case report (unique occurrence or outcome in a single subject)
Few (approx 3-10): case series (unique outcome in a few similar subjects)
Many (more than 10): survey

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Yes surveys? can be…

A

cross sectional or retrospective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

retrospective w/ known outcome

A

purpose to determine CAUSE of outcome

—Subjects w/outcome vs subjects w/out outcome

CASE CONTROL!
—-Keys: quick method to “possibly” determine cause of outcome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

retrospective w/o known outcome

A

compare 2 or more groups; collect/analyze data/measure difference between groups

COHORT!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

case control

A

Keys: quick method to “possibly” determine cause of outcome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

cohort

A

Naturalistic study

Initial data then check back in a year to see changes etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

no survey? Can be…

A

prospective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

prospective

A

Compare 2 or more groups and measure outcome

RANDOMIZATION (important for strength of evidence!!)
Everyone has equal opportunity to be in either group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

M: state whether fail to reject (Accept ) or reject Ho

A

Reject Ho when p < alpha

Accpet Ho when P > alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

N: state the type of error that can occur. What is the potential cause?

A

Error is POSSIBLE but doesn’t always occur
P < alpha → 1 < 2 → type 1 error possible
P > alpha → 2 > 1 → possible type 2 error

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Type 1 error (alpha error)

A
  1. Reject Ho when Ho should be accepted (false-pos)
  2. One reason for type 1 error: CHANCE.
  3. Saying theres a diff when there is no diff.
  4. Probability of type 1 error = p-value x 100
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Type 2 error (beta error)

A
  1. Accepted Ho when Ho should be rejected (false-neg)
  2. Saying there is no diff when there is
  3. Two reasons for type 2 error: chance and/or small n
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

O: Define ‘randomization.’ (2 cards for O) (list purpose of randomization here)

A

Reduce bias
Try to make groups equal w/ demographics
To validate selected statistical tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

O continued: describe how study was Strengthened or Weakened by including or not randomization in study design

A
  • All pts in study have equal opportunity to be in intervention or control
  • Goal: study groups to be as equal as possible so that only diff b/w groups is one getting intervention vs control
  • So, if a diff → attributed to intervention (cause/effect relationship)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

P: State if primary endpt is subjective or objective

A

Subjective: pt can have influence on results
Objective: pt does not have influence on results
Very important for type of blinding done in the study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

CCT ** PLZ KNOW **

A

Best study design to measure and quantify differences in effect between 2 or more groups and cause and effect

Most robust study design to measure and quantify differences between an intervention and control group

Study is conducted to determine the outcome by the intervention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

CCT process?

A

Population —> sample —> CCT —> conduct study using good methods —> results —> analysis via statistical tests —> interpretation —> formulate an evidence-based conclusion —> extrapolate to/apply within the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

R: Was the duration of clinical trial sufficient to answer objective?

A

Yes/no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

BMP

A

Basic metabolic panel
-provides test, result, and reference interval

Na | Cl | BUN / glucose
K | HCO3- | Cr \
(Fish bone thing)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is per-protocol (PP)?

A
  • bad on own (RED FLAG!)
  • Bias can be present
  • Method of analyzing result from only pt who completed 100% of CCT.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

T: How many pts did not complete the study? How do pts not completing the study affect the primary endpt results?

A

Evaluate number of and reasons for dropouts

Throw out incomplete pts = bias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

U: describe whether the primary endpt was clinically diff b/w intervention and control group. (2 cards)

A
  • Every result needs to be evaluated in terms of diff present
  • Not every study result that is statistically signif is clinically diff
  • P-value says NOTHING abt magnitude of diff in outcome effect b/w intervention and control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

U continued: p values and their significance in determining if clinically different

A

-Do not automatically conclude that all p alpha → not clinically diff
—No diff in outcome effect b/w intervention & control
-CAUTION
P > alpha does NOT mean results are equal, similar, or equivalent → accept Ho (NO DIFF STATEMENT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

randomized prospective Groups receive both “treatments?”

A

yes –> crossover

no –> CCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

crossover

A

Pt serve as own control. Return to baseline (back where you started)
Typically used when testing bioequivalence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

not randomized prospective

A

cohort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Locate reputable disease state practice guidelines using PubMed.

A

“Practice guideline” “insert disease state here” using MeSH (apparently…. Works without it too JS) but for the love don’t tell him if you used google or Samford Lib or the associations website.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

strengths of disease state practice guidelines

A

Always updated with most recent findings….

Relatively universal recommendations… aka you won’t look like a fool if you cite your source

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

limitations of P/G

A

only available for commonly studied diseases → no rare ones

not hard-set data; situational evaluations plus best judgement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Read and interpret disease state practice guidelines

A

Rank evidence rating from guideline to give informed recommendations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

CCT PLZ KNOW WORD FOR WORD

A

Best study design to measure and quantify differences in effect between 2 or more groups and cause and effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

CCT process?

A

Population —> sample —> CCT —> conduct study using good methods —> results —> analysis via statistical tests —> interpretation —> formulate an evidence-based conclusion —> extrapolate to/apply within the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

CCT peer review joural

A

Goal is to inc quality of published article/study

Manuscript sent to journal editor —> peers for review —> either rejected or tentatively accepted w/comments for author to improve/clarify

Manuscript may go back and forth for revisions until accepted/published (2-4 month process,hopefully completed within 9-12 months)

Signs it underwent peer review:
“Received (date), revised (date), and accepted (date)”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

CCT trial registration

A

(clinicaltrials.gov)

All studies should be registered into this database so results of all projects are accounted

Reasoning: some researchers weren’t publishing “neg” trials (when pts were harmed)

Also to reduce publication bias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Funding for CCT

A

Gov, private orgs, foundations, and drug companies

Quality of study should be assessed regardless of funding source

BUT don’t assume a study is bias just bc of its sponsor (it’s too expensive to create a purposefully bias study, esp for drug companies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Evaluating a CCT

A

CCT —> study objective/purpose —> primary endpoint —> primary endpoint “type” —> create null hypothesis for primary endpoint

sample —> randomization —> intervention vs control —> results —> endpoint result p vs alpha —> > > >

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Primary endpoint

A

Outcome that is measured to determine if a difference exists between the intervention and control

Capable of answering the study question using proper measuring techniques and appropriate definitions

okay to have secondary endpts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

secondary endpts

A

Should NOT be focus of study

Sometimes primary has p>alpha so investigators try to use secondary endpoints to convince reader that intervention is still good, but study is set up based on primary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Primary endpoint “type” subjective vs objective

A

Blinding type dec bias
Double blinding is best for Subjective
Objective can be open, single or double
Rule of thumb: double blind if possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Primary endpoint “type” surrogate vs clinical

A

surrogate: Endpoint easily and quickly measured (LDL, weight, not always correlated to clinical outcome)
clinical: Ultimate outcome; major importance to pt (death, MI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

how to Create Ho for primary endpoint

A

There is…

No difference
Between (intervention) and (control)
In (measurable endpoint)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

nominal data

A

yes/no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

ordinal data

A

scale or ranking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

continuous data

A

equal intervals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

evaluate CCT: sample

A

Conduct a power analysis (at least 80%) to est appropriate sample size (n)
Difference is est between intervention and control (gamma rate)
Inclusion and exclusion criteria (all CCTs have this)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

evaluate CCT: randomization

A

Keys: reduce bias, needed for stats to be valid, results in very similar groups
Intervention group and control group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

evaluate CCT: results

A

Intention to treat (ITT) to include all pt results regardless of if they finished the CCT

Per-protocol (PP) results of only those finishing entire CCT are analyzed

Dropout rates should be similar between intervention and control groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

evaluate CCT: endpt results

A

Alpha always given at beginning of study before research begins

Can only use p-value for statistical purposes

Can’t say something is better by X%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

V: Is the primary endpoint considered a surrogate or clinical endpoint? Briefly discuss the significance of endpoint type (Surrogate card)

A

Surrogate endpoints are NOT incorrect or inappropriate to measure in a study
Usually measured to quantify the degree of pharmacological effect produced by the intervention group
Endpoints used to correlate a clinical effect
DON’T GUARANTEE occurrence of a clinical event

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

V continued: Is the primary endpoint considered a surrogate or clinical endpoint? Briefly discuss the significance of endpoint type (clinical card)

A

Clinical endpoints are absolute outcomes that a pt can experience
Death, MI, renal failure, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

W: Discuss the clinical usefulness of the primary endpoint results

A

Are results useful to be applied in practice?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

X: Do the investigators adequately present in the Discussion section the key conclusions in an unbiased manner? Are these supported by the study results? Explain your response.

A
  • Discussion section provides an interpretation of study results
  • Usually includes comparison of results to similar studies
  • Should include study limitations and how these could affect the study
  • Can contain bias in terms of interpreting and applying results so watch out
67
Q

Y: Identify the funding source for this study. Evaluate the significance of the funding source for the research project. Was it bias due to who the funds came from?

A
  • Don’t automatically discredit a study due to the funding source (drug co)
  • Evaluate entire study to determine strengths and limitations, not just where the funding source is
68
Q

Z: is the clinical trial title misleading after reading the entire study? Explain.

A

Title should be an appropriate overview of study question

Good study title is objective, clear, unbiased, and declarative

69
Q

AA: briefly discuss the significance of study results (not just primary endpoint) and how well study applies to practice. Include to who these results can be extrapolated. “Tie together” all the study strengths and limitations and how these results can be used in practice (long list of 15 factors)

A

-Discuss how responses can be used collectively to formulate an overall critique of the CCT

Factors

  • Study strengths/limitations
  • Objective
  • Endpoints
  • Inappropriate control group used
  • Interventions
  • Sample size/power analysis
  • How results/data is presented
  • Measures of association calculations
  • Selection bias, recall/reporting errors, ancillary therapy
  • Conflict-of-interest
  • Rationale for conducting the study
  • Patient exclusion/inclusion criteria
  • Dosing titration differences/wash-out period if needed
  • Data collection methods
  • Type I or II error possibilities
70
Q

What is CONSORT and its purpose?

A

-consolidated standards of reporting trials
-established to improve the quality of reporting clinical trials in published lit
—Supported by an inc # of journals
-Other research types can report the investigation using the style of reporting a CCT
—Do not assume that all publications using this format are CCTs

71
Q

Define publication bias

A

Suppression and/or failure to present data regarding negative study results

72
Q

Define diagnostic

A

determine/confirm presence of disease

73
Q

Define baseline

A

“normal” for pt — often measured before drug therapy starts

74
Q

Define monitor

A

“Assessment” — determining efficacy and/or safety of therapy

75
Q

Define direct pt PK parameters

A

adj of medications for individual pt

76
Q

Define Specific drug levels

A

Determine toxic or subtherapeutic serum [ ]

77
Q

Define reference range

A
  • A statistically-derived numerical range obtained by testing a sample of healthy pt
  • WNL = within normal limits
78
Q

Define therapeutic range

A

Range of drug [ ] w/n which the probability of the desired clinical response is relatively high and the prob of toxicity is relatively low

79
Q

Define critical value

A
  • Result outside of ref range that indicates high risk of mortality
  • Note: these values are set by policies in the lab and are usually flagged for review
80
Q

BMP

A

Basic metabolic panel

-provides test, result, and reference interval

81
Q

Endpoint result p-value < alpha —> yes?

A

Statistically significant/different —> reject null hypothesis —> possible for clinical difference —> assess difference in primary endpoint results between the 2 groups —> POSSIBLE type 1 error (chance is an option

82
Q

Probability of type 1 error (alpha error):

A

Take p-value x100 to get % (% = probability of rejecting TRUE Ho)
This % also = probability that chance is reason for difference
This % is alsooooo probability of having type 1 error

83
Q

Endpoint result p-value < alpha —> no?

A

Not statistically significant/different —> accept Ho —> NO clinical difference —> POSSIBLE for type 2 error

Can’t use p value to determine probability of accepting false Ho, chance, or Small n for being reason for no difference or of having type 2 error

84
Q

two reasons for type 2 error (beta error)

A

Chance

Small n

85
Q

relationship b/w power & n

A

Inc power by inc n which dec beta error possibility

86
Q

power =

A 
Power = 1 - beta
Power = ability to detect a difference in outcome between intervention and control if a difference truly exists
87
Q

beta error should be < ___ %

A

20%

88
Q

“landmark trial”

A

One CCT isn’t sufficient to adopt therapy as first choice to treat pts unless it’s a “landmark trial” which means you can apply it today

89
Q

how CCTs are applied to practice

A

Usually combine results of multiple trials for evidence to incorporate newly developed therapy into practice/changing existing method of treatment

90
Q

why are Both appropriately and poorly designed CCT published?

A

All CCTs may not translate into clinically useful info

Better quality if resulting from well-designed study

91
Q

A: article citation

A

use AMA

92
Q

B: state the type of study that best describes the investigation + how you determined it… also, discuss if it was appropriate to “answer” the study question

A

Uniform framework: always regardless of type

Primary study designs

93
Q

uniform framework

A

Assignment: sample from pop assigned to group
Assessment: study is conducted with this sample and results collected
Analysis: results are analyzed
Interpretation: investigators interpret the results (what do these mean/tell us?)
Extrapolation: apply these results to the population

94
Q

Format and content of CCTs

A

Title: indicate type of study design and purpose
Abstract: a brief overview of research; errors
Intro: research background; clinical trial objective
Methods: focus evaluating; study design/randomization, inclusion/exclusion criteria, setting, intervention/control, blinding, endpoints/outcomes, follow up procedure, sample size calculations and power analysis, any other analyses
Results: demographics of subjects, subject drop-outs/compliance, endpoints quantified, additional analyses, safety assessments
Discussion: interpret results, compare to other studies, generalizability, limitations
Acknowledgements: other contributors, FUNDING SOURCE, peer review dates/manuscript, acceptance date if applicable, registration
References/bibliography

95
Q

CCT is primary study design to…

A

use as evidence to make decisions

96
Q

CCT design

A

From population, sample pts randomized to intervention or control
Pts followed prospectively over time and outcome is measured
Difference in the outcome measure = assessed
Results used to make recommendations

97
Q

cross-over

A

Study conducted to directly measure differences in outcome effect b/w groups

98
Q

cross-over diff from CCT

A

study pts get both ‘therapies’
Need wash-out period between ‘therapies’ to pts return to BASELINE
Pts are own control… dec inter-pt variability
Need smaller sample size

99
Q

cross-over design

A

From population, sample selected and randomized to intervention or control
Pts followed prospectively and outcome is measured
Pts stop ‘therapy’ and enter washout phase of the study
Pts are converted to the ‘other therapy’ and followed prospectively and outcome is measured again
Diff in outcome measure is assessed

100
Q

case-control

A

Outcome is known → study conducted to determine etiology/reason for outcome

Study conducted to determine the cause of adverse event (like MI)

101
Q

case-control design

A

From population, one group with outcome ID (case group); another group from population ID but without outcome (control)
Two groups of pts are as equal as can be with exception to case group having the outcome and controls do not
Pt data RETROSPECTIVELY reviewed to ID diff between case/control
Diff may be possible reason of adverse event

102
Q

Cohort (prospective)

A

Gathers data ‘naturally’ from a group by following/monitoring pts without intervention
Two groups can be compared, but groups may not be similar so diff in outcomes may not be true
Conducted to determine an outcome without intervention

103
Q

Cohort (prospective) design

A

Sample from population naturally taking the ‘intervention’ is selected along with a sample of pts naturally taking control…
Pts are followed prospectively over time and outcome is measured
A diff in the outcome measure is assessed
Major problem = two groups may not be equal and diff measured may be biased

104
Q

Cohort (retrospective)

A

Gathers data ‘naturally’ from a group
Conducted to determine an outcome without intervention
Two groups can be compared, but groups may not be similar so diff in outcomes may not be true

105
Q

Cohort (retrospective) design

A

Sample from population naturally taking the ‘intervention’ is selected along with a sample of pts naturally taking control…
Pts data/history are retrospectively reviewed to gather outcome info
A diff in the outcome measure is assessed
Major problem = two groups may not be equal and diff measured may be biased

106
Q

cross-sectional

A

Survey

Gathering data at one point in time

107
Q

case report (Case series)

A

Occurrence of outcome in a single pt (small group)
Difficult to use as evidence
Could be by chance that outcome happened

108
Q

C: state the QUESTION that is to be answered by conducting this study. Was the study purpose clearly stated?

A

Stated in the introduction section (usually last paragraph)

Convert the study purpose/objective into a question

109
Q

D: Briefly discuss the rationale for conducting this study. Do the investigators provide a discussion of how this study will be better designed to provide more definitive results and/or overcome prior study limitations? Is it another “me too” or “first of it’s kind” to answer a question?

A

Each study has a reason for being done

Rationale is presented in the intro section

110
Q

E: State the primary endpt (dependent variable). Was this appropriate and were precise methods used to measure it? Other ref may be needed to answer/

A

Each study will measure ONE outcome to use to answer the study question

Data gathered for primary outcome analyzed to…

  • –Determine if diff exists b/w intervention and controls
  • –Quantify the diff

inadequate/inappropriate outcome measurement techniques lead to poor study design and meaningless results

111
Q

F: state the intervention groups and control groups. Is an appropriate intervention being compared to an appropriate control?

A

Every CCT has an intervention and a control

Outcome results of these groups are measured and compared to determine diff and quantify said diff.

“Magnitude of effect”

Placebo as control is appropriate for many studies est if researching to determine cause-and-effect

112
Q

Compare effect of intervention to…

A

Est therapy to determine if intervention is better OR placebo to determine if intervention has any therapeutic effect

113
Q

G: State the Ho (based upon primary end pt)

A

“There is NO DIFF b/w [intervention] and [control] in the [endpoint of measure]” → GENERIC STATEMENT
Statistical result is used to determine whether Ho should be rejected or ‘accepted’ (aka failed-to-be-rejected)

114
Q

H: evaluate the pt inclusion/exclusion criteria. Were these appropriate for the study question? Selection bias? How do these affect the extrapolation to the pop?

A

Inclusion and exclusion criteria are important to know so the study results can be EXTRAPOLATED from study to pop

Excluding complex pts is typical to reduce variability in results from the groups
Usually excluded: preg, lactating, renal/liver failure

115
Q

I: define “power” and the purpose of a power analysis. Was power analysis done? If so, was the calc and resulting % appropriate? Were appropriate variables included?

A

Power: ability of a study to detect the diff in outcome effect b/w intervention & control if there is a diff.
Minimum power = 80%
Alpha = 0.05

General principle: INC power by INC n which DEC beta-error (type 2)

  • –Large diff in outcome effect require smaller n
  • –Small diff in outcome effect require large n

Gamma = estimated diff in outcome effect b/w the intervention and control

Prior research is used to guestimate expected outcome

116
Q

power analysis

A

a process to calculate an adequate # of pts to enroll into study so study is able to detect and quantify the diff in outcome effect between intervention and control

117
Q

J: state the type of data that primary endpt is being presented and used in the calculation of p-value

A

Nominal: yes/no data, mutually exclusive
Ordinal: ranked/scale data
Continuous: data that have equal intervals
The data that has “an effect” on the statistical tests used and data presentation methods

118
Q

K: state the actual results for the primary endpt plus p-value. Interpret p-value in terms of a probability. State the alpha value, is this value stated or assumed? Is an appropriate alpha value included?

A

All statistical analyses compute a p-value, which informs the researched whether result is statistically signif or not

Compare p-value to alpha-value

Setting alpha above 0.05 may lead to less robust study while above 0.05 leads to more stringent studies

A p-value says nothing about the magnitude of diff of the outcome effect b/w the intervention and control

119
Q

P-value = probability value

A

P < 0.05 → statistically signif diff

P > 0.05 → no statistically signif

120
Q

L: state whether the primary endpt was or was not statistically signif

A

P < alpha = statistically signif → reject Ho

P > alpha → not statistically signif & inconclusive

121
Q

Point of care testing

A

Dx testing performed at or near the site of pt care

122
Q

adv of Point of care testing

A

reduced turn-around time, test portability, and pt self-testing

123
Q

disadvantages of Point of care testing

A

misuse or misinterpretation of results, documentation errors, inappropriate disposal of testing material, and quality assurance issues

124
Q

International Normalized Ratio (INR)

A

Normal ref range = 0.9 - 1.0

Used for efficacy and safety of warfarin
Therapeutic range for warfarin = 2.0-3.0 or 2.5-3.5 (depending on disease)

Used as dx tool (liver dysfx, malnutrition)
Standardized monitoring parameter recommended by american college of chest physicians

125
Q

INR equation

A

= ( prothrombin sec of pt / prothrombin sec of control ) ^ ISI

ISI based on thromboplastin reagent used in each lot and reported in the package

***High potential for human error

126
Q

Absolute neutrophil count (ANC)

A

Risk of infection is greatly inc w/ ANC less than 500/mm^3

Commonly associated with chemotherapy agents/tx

127
Q

ANC equation

A

WBC x (% neutrophils + % bands) / 100

128
Q

CMP

A

Comprehensive metabolic panel

  • Lists component, pt value, standard range, and units
  • Same as BMP plus GFR, Ca, albumin, protein total, etc
129
Q

Other acronyms/terms in lab value interpretations

A
  • SMA-7: sequential multiple analyzer
  • Chem-7, Chem-8
  • Chem Profile 20
130
Q

Most common timing of tests (4)

A

Hourly, daily, monthly, annually

131
Q

Specimens usually tested in blood (venous or arterial) (2)

A
  • Plasma = fluid, acellular portion of blood; Buffy layer (55%)
  • Serum = liq that remains after the fibrin clot is removed from plasma
132
Q

Specimens usually tested for excretion

A

Urine

Stool

133
Q

Other fluids tested besides blood and excretions (5)

A
  • CSF
  • wound drainage
  • sputum
  • tissues
  • gastric secretions
134
Q

Classifications of Lab Data: qualitative test

A

Not a specific amt (aka pos or neg)

135
Q

Classifications of Lab Data: quantitative test

A

Reported as an exact numeric measurement

-Abnormal lab in a normal pt is NOT always abnormal

136
Q

Classifications of Lab Data: semi-quantitative

A

Reported w/ various degrees of neither pos nor neg w/o exact #

137
Q

Sensitivity

A
  • Ability of test to ID positive results in pts who actually have the disease (true positive rate)
  • Also refers to range that can be accurately measured
138
Q

Specificity

A
  • Percent of negative results in people without the disease (true negative)
  • The lower the specificity number, the higher chance of false positive (could be expensive if it leads to more tests/procedures)
139
Q

What is included in a complete blood count (CBC)

A

RBCs, WBCs, Hgb, Hct, RBC indices, reticulocyte count, platelets/thrombocytes

140
Q

CBC with differential

A

analysis of the cells of WBCs
WBCs and platelets are actual counts
HgB (#) and Hct (%) → based on volume and may be artificially high in pts with dehydration

141
Q

Anion Gap (AG or “R”)

A

Blood and urine anion gap
Blood: associated with metabolic acid/base disorders
Urine: associated with diagnosis of renal tubular acidosis (RTA) types 1-4
Blood anion gap normal range 5-12

142
Q

AG or R equation

A

Serum Na = R + [ (HCO3- + Cl-) ]

R = Na+ - (HCO3- + Cl- )

R=unmeasured acids (like lactate, phosphates, sulfates, and proteins which equals 5-12 in normal situations)
May be artificially low in pts with low albumin levels
Levels R>15 is metabolic acidosis

143
Q

Correcting for albumin

A

Total Ca includes ionized and bound form of Ca
Total Ca (8.8-10.2 mg/dL)
Ionized Ca active form (4.5-5.6 mg/dL)
Need to correct for albumin levels less than 4 g/dL (hypoalbuminemia) for Ca and phenytoin

144
Q

Corrected phenytoin equation

A

= pt lvl / [0.9 x (pt albumin/4.4) + 0.1 ]

145
Q

Corrected Ca equation

A

= [(4-albumin) x 0.8] + measured serum Ca

146
Q

Common calculations

A 
Correcting for low albumin
Calcium
Phenytoin (Dilantin)
Anion gap
Absolute neutrophil count (ANC)
International normalized ratio (INR) (calculated for you)
147
Q

Arterial blood gases (ABGs)

A

Must get history and physical exam
Draw ABGs and BMP simultaneously
BMP: HCO3-; 22-28 mEq/L (in fish bone structure bottom middle)

148
Q

ABGs and normal ranges are..

A 
pH: 7.35-7.45
pCO2: 35-45 mmHg
pO2: 80-100 mmHg
calculated HCO3: 22-26 mEq/L
O2% saturation: greater than 95%
149
Q

Albumin

A

Normal albumin 3.5-5 g/dL
Synthesized in liver
Plasma osmotic P, binding and transportation of various hormones, anions, FAs, and drugs!!!

150
Q

Albumin takes ~___ days to change in MOST situations

A

20 days!!

Takes ~8 days to see a 25% change in albumin after significant liver damage

151
Q

Hepatic function markers

A

AST, ALT, alkaline phosphatase

Elevated AST and/or ALT suggest hepatocyte damage or hepatic inflammation (not indication for etiology or severity of liver dysfunction)
AST (aspartate aminotransferase): present in heart and other tissues; half life of 17 hrs
ALT (alanine aminotransferase): more specific for liver; half life of 47 hrs

152
Q

Hepatic dysfunction

A

True liver failure is based on multiple factors

  1. Child-Pugh Classification
  2. Model end stage liver disease (Meld Score)
153
Q

Child-Pugh Classification

A

Uses albumin, total bilirubin, prothrombin time or INR, ascites, encephalopathy
Used to ID classification in liver disease and adjust meds
There’s a chart to determine severity (slide 37 if interested)

154
Q

Model end stage liver disease (Meld Score)

A

Uses SCr, total bilirubin, INR, and serum Na

Used to ID liver transplant and severity of disease (diagnostic tool)

155
Q

Renal function

A

Use Cockcroft and Gault to est CrCl

Don’t forget multiply female by 0.85
DO NOT use decimals clinically
Use ABW or IBW where appropriate

156
Q

WBC differential

A
  • must add to 100
  • Neutrophils = most numerous WBCs (aka segs or polys)

(Chart pic looks like weird X)
WBC >Hbg (top) < Plt
HCT (bottom)

157
Q

Causes of WBC elevation

A

-Neutrophilia: infection or inflammation
—Left shift: presence of immature neutrophils/”bands”
-Eosinophilia: parasitic infection or allergic response
-Basophilia: chronic inflammation
-Monocytosis: associated with recovery state of bacterial infection (TB)
-Lymphocytosis: viral infection or lymphoma

158
Q

Sources of lab errors: pt factors

A

Age, gender, wt, diet, preg, chronic disease, incorrect pt history

159
Q

Sources of lab errors: Improper handling of specimen

A

Using incorrect tude (INR)

Hemolysis of blood sample (K)

160
Q

Sources of lab errors: timing of lab draw

A

Issue if trying to do PK

161
Q

Sources of lab errors: error with analysis

A

Use of incorrect reagents

Mislabeling samples

162
Q

Sources of lab errors: medications

A

False pos for opiates on UDS with mutli drugs (ranitidine, sertraline, naproxen, others)

163
Q

Clinical pearls

A

Do not order lab tests unless it will be used in decision making
Be skeptical of unusual results → better to repeat a test than act on incorrect data
Treat pts NOT NUMBERS

Pharmacotherapy 1 (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions